Celcuity Inc. (CELC)
| Market Cap | 4.30B +147.3% |
| Revenue (ttm) | n/a |
| Net Income | -192.89M |
| EPS | -3.89 |
| Shares Out | 48.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 618,188 |
| Open | 92.15 |
| Previous Close | 90.79 |
| Day's Range | 87.63 - 92.20 |
| 52-Week Range | 44.42 - 151.02 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 163.54 (+85.61%) |
| Earnings Date | Aug 13, 2026 |
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $163.54, which is an increase of 85.61% from the latest price.
News
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of ...
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CELC--CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law.
Celcuity announces NCCN recommendation for Revtorpyk combination
Celcuity (CELC) announced that Revtorpyk in combination with fulvestrant, with or without palbociclib, is recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncol...
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutat...
Short Report: Bears book profits in Celcuity
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the…
Celcuity price target raised to $178 from $171 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Celcuity (CELC) to $178 from $171 and keeps a Buy rating on the shares. Celcuity’s Revtorpyk approval came in as expected with a…
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch of its newly approved breast cancer drug and treatment-tolerability concerns overshadowed the com...
Celcuity price target raised to $155 from $145 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $155 from $145 and keeps a Buy rating on the shares following the FDA approval of Revtorpyk. Published first…
Celcuity price target raised to $177 from $160 at Citizens
Citizens raised the firm’s price target on Celcuity (CELC) to $177 from $160 and keeps an Outperform rating on the shares. Celcuity’s early FDA approval of Revtorpyk marks its transition…
Celcuity Transcript: FDA announcement
FDA approved REVTORPYK for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, based on strong Phase III data showing significant improvements in progression-free survival and a favorable safety profile. Commercial launch is planned for late Q3, with robust support and market adoption strategies.
Celcuity Press release: FDA announcement
Celcuity issued a press release on July 14, 2026, disclosing material business information to investors.
Celcuity Slides: FDA announcement
Celcuity has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Celcuity announces FDA approval of Revtorpyk
Celcuity (CELC) announced that the U.S. Food and Drug Administration approved REVTORPYK for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative,...
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, ...
Celcuity Slides: Corporate presentation
Celcuity has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
US FDA approves Celcuity's breast cancer drug
The U.S. Food and Drug Administration has approved Celcuity's drug for an advanced form of breast cancer, the regulator said on Tuesday, making it the company's first product to gain m...
FDA approves Celcuity’s gedatolisib combo for certain breast cancers
The Food and Drug Administration approved gedatolisib or Revtorpyk, from Celcuity (CELC), in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor-positive, human...
Celcuity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The lead PAM pathway inhibitor shows strong efficacy and tolerability in advanced breast cancer, with regulatory milestones ahead and solid commercial infrastructure. Clinical data support use in wild-type and mutant cases. Pipeline expansion includes prostate cancer. Financial runway is secured through 2029 for trials and commercialization.
Celcuity Slides: FY 2026
Celcuity has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Celcuity Transcript: Jefferies Global Healthcare Conference 2026
Gedatolisib demonstrated strong efficacy in phase III breast cancer trials, with both doublet and triplet regimens doubling progression-free survival versus control. Regulatory review is progressing, commercialization plans are advanced, and the drug is positioned as a potential new standard of care with a robust cash runway through 2029.
Celcuity prices $500M convertible senior note offering
Celcuity (CELC) announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032. The aggregate principal am...
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for t...
Celcuity price target lowered to $171 from $189 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Celcuity (CELC) to $171 from $189 and keeps a Buy rating on the shares following ASCO data from VIKTORIA-1 study 2 evaluating gedatolisib…